Cite
Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity.
MLA
Kosiborod, M. N., et al. “Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity.” New England Journal of Medicine, vol. 389, no. 12, Sept. 2023, pp. 1069–84. EBSCOhost, https://doi.org/10.1056/NEJMoa2306963.
APA
Kosiborod, M. N., Abildstrøm, S. Z., Borlaug, B. A., Butler, J., Rasmussen, S., Davies, M., Hovingh, G. K., Kitzman, D. W., Lindegaard, M. L., Møller, D. V., Shah, S. J., Treppendahl, M. B., Verma, S., Abhayaratna, W., Ahmed, F. Z., Chopra, V., Ezekowitz, J., Fu, M., Ito, H., & Lelonek, M. (2023). Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity. New England Journal of Medicine, 389(12), 1069–1084. https://doi.org/10.1056/NEJMoa2306963
Chicago
Kosiborod, M. N., S. Z. Abildstrøm, B. A. Borlaug, J. Butler, S. Rasmussen, M. Davies, G. K. Hovingh, et al. 2023. “Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity.” New England Journal of Medicine 389 (12): 1069–84. doi:10.1056/NEJMoa2306963.